IN-ARMOR is set to impact the AMR market with ISI based drugs that utilise innate immunity to fight pathogens reducing the need for antibiotics, starting with the Inflammatory bowel disease (IBD) (i.e., gastro-intestinal (GI) indications.

Development of the ISI based AMP drugs will form the foundation, crucial in the advancement of innovative therapies aimed at tackling the challenge of AMR. IN-ARMOR´s pathway into topic outcomes and long-term destination impacts is described below. Our results are directly related to the HORIZON-HLTH-2022-DISEASE-06 topic outcomes and expected long term impacts.

IN-ARMOR topic outcomes and long-term destination impacts is described below.